MasterCard Inc vs Mesoblast Limited — how do they compare? MasterCard Inc trades at $559.59 (market cap $493.34B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: MasterCard Inc is far larger — about 228.4× Mesoblast Limited's market cap, and MasterCard Inc pays a 0.62% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MA | MESO | |
|---|---|---|
Market Cap | $493.34B | $2.16B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $598.96 | $20.96 |
52-Week Low | $471.55 | $12.88 |
Enterprise Value | $506.38B | $2.17B |
Dividend Yield | 0.62% | — |
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $563.17, up 0.04% today, with a bullish technical signal and strong institutional buying. The stock shows robust fundamentals, with revenue growing from $22.2B in 2022 to $32.8B in 2025 and net income margins above 45%. Recent earnings beats and a consensus price target of $660.85 reflect optimism, though high valuation ratios like a P/E of 30.98 warrant caution.
Outlook is positive due to consistent earnings growth, expanding digital payment initiatives, and analyst buy ratings. Risks include competitive pressures from new payment technologies and regulatory scrutiny. The stock offers upside potential but requires monitoring of valuation and market shifts.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Trailing returns across standard periods
Latest headlines on both assets
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →